Ofloxacin (ofloxacin)

No dosing information is available for this tab.

No dosing information is available for this tab.

Specific drug interaction studies have not been performed using ofloxacin ophthalmic or otic preparations. However, since systemic absorption may occur following topical application of ofloxacin to the eye or ear, the possibility of drug interactions such as those reported with systemic administration of some quinolone anti-infectives (e.g., interactions with theophylline, caffeine, oral anticoagulants, cyclosporine) should be considered.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

There is no enhanced messaging for this drug.

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

• No disease contraindications

There is no enhanced messaging for this drug.

Rare or Very Rare

• Stevens-johnson syndrome
• Tachycardia
• Toxic epidermal necrolysis

More Frequent

• Ocular irritation

Less Frequent

• Blurred vision
• Dizziness
• Dry eye
• Dysgeusia
• Earache
• Erythema of ear
• Eye tearing
• Foreign body sensation of eye
• Hypoesthesia
• Ocular itching
• Ocular pain
• Ocular redness
• Paresthesia
• Periorbital edema
• Photophobia
• Vertigo

Rare or Very Rare

• Dizziness
• Drug-induced hot flash
• Dyspepsia
• Ear itching
• Eczema
• Facial edema
• Fever
• Flushing
• Folliculitis
• Headache disorder
• Nausea
• Pharyngitis
• Rhinitis
• Sinusitis
• Skin inflammation
• Skin rash
• Tinnitus

No enhanced messaging available.

No enhanced messaging available.

There are no adequate and controlled studies to date using ofloxacin 0.3% ophthalmic solution or ofloxacin 0.3% otic solution in pregnant women, and these preparations should be used during pregnancy only when potential benefits justify possible risks to the fetus.

Reproductive studies in rats and rabbits using oral ofloxacin dosages as high as 810 and 160 mg/kg daily (equivalent to 9000 and 1800 times the maximum recommended daily ophthalmic dosage, respectively) did not reveal evidence of teratogenicity. However, embryocidal effects were reported in rats and rabbits receiving such dosages. Decreased fetal body weight and retardation in the degree of ossification and minor skeletal variations, such as cervical ribs and shortened or absent 13th ribs, were reported in the rats; increased fetal mortality was reported in the rabbits. Perinatal and postnatal studies in rats given oral ofloxacin dosages up to 360 mg/kg daily (4000 times the maximum recommended daily ophthalmic dosage) revealed a decrease in food intake during gestation and an increase in food and water intake during lactation, but did not reveal evidence of adverse effects on late fetal development, labor, delivery, lactation, neonatal viability, or growth of the offspring.

It is not known whether ofloxacin is distributed into milk following topical application to the eye or ear; however, ofloxacin is distributed into milk following oral administration.

Because of the potential for serious adverse effects of ofloxacin in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the woman.

No enhanced messaging available.